ABSTRACT Fifteen year chronic bronchitis mortality was investigated among 17 717 male civil servants aged 40-64 years participating in the Whitehall Study. Associations were assessed between mortality and Medical Research Council standardised questions about chronic phlegm production and breathlessness, and a measure of lung function. Low FEVI was the most powerful single predictor of mortality; controlling for age, smoking habits and employment grade, the relative hazards ratio (RHR) was 20. Using mortality rates standardised for age and smoking, the proportion ofmortality in the total population statistically attributable to low FEV1 (population excess fraction) was 57%. Breathlessness while walking on the level was the best predictor among the questions and combinations ofquestions; the relative hazards ratio was 12 and the population excess fraction, 39%. A Medical Research Council definition of chronic bronchitis including chronic phlegm production and breathlessness was also strongly associated with chronic bronchitis mortality (RHR = 13); however, the population excess fraction was only 20%. This definition identified only 30% of the 64 deaths, and added almost nothing to prediction by FEVy alone. The results suggest that although the combination ofchronic phlegm production and chronic airflow limitation is strongly associated with mortality from chronic bronchitis, the presence ofchronic phlegm production alone is not associated with mortality.
One of the definitions of chronic bronchitis recommended by the Bronchitis Research Committee of the Medical Research Council in 1965' 2 includes report of both chronic phlegm production and breathlessness, where breathlessness was used as an indication of chronic airflow obstruction. This definition was based on the belief that individuals reporting chronic phlegm production would later become disabled by chronic airflow obstruction. 3 Other definitions of chronic bronchitis have been proposed, including chronic phlegm production alone, and cough with expectoration not attributable to other lung diseases.' 4Recent studies have shown that chronic phlegm production and chronic airflow obstruction are two separate disease processes.S'0 Fletcher and Population excess rates and population excess fractions'6 were calculated using mortality rates standardised for age and smoking.
Results
Prevalence rates ofthe various measures of respiratory impairment ranged from a high of 23-1% for "usually have phelgm in winter" to a low of 0-9% for "low FEV, and persistent and increased phlegm and breathlessness" (table 1) . Approximately half of the men who reported breathlessness or had a low FEV, also reported persistent phelgm production. The numbers of deaths attributed to chronic bronchitis were small. None of the measures identified all 64 deaths; the majority of deaths were identified by the presence of low FEVY alone (n = 45) or by low FEVY plus breathlessness (n= 50). Adding "persistent and increased phlegm and breathlessness" identified only one additional death to those identified by low FEVY.
Smoking was a major risk factor for chronic bronchitis mortality. Only one death occurred among never smokers; there were 14 deaths (21-9%) among exsmokers and 49 (76 6%) among smokers. All of the measures except "persistent phlegm without breathlessness" were significantly associated with chronic bronchitis mortality in Cox proportional hazards regression models (table 1). The relative hazards ratios were highest for low FEV, alone or in combination with breathlessness or "persistent and increased phlegm and breathlessness" (RHR = 19-26). The ratios were lower, but still large (RHR = 12) for "breathlessness walking on the level" and "persistent and increased phlegm and breathlessness." Excluding men who also reported persistent phlegm production markedly reduced the relative hazards ratios for breathlessness (11-7 to 3 4) and low FEV, (19-9 to 4 4), which suggests that the presence of both persistent phlegm production and airflow limitation predict higher mortality from chronic bronchitis. However, persistent phlegm production without breathlessness or low FEV, was not significantly associated with mortality.
Of men reporting breathlessness, 319 (32-6%) also had low FEVY; and 153 (52-6%) of men with "persistent and increased phlegm and breathlessness" also had low FEV, . Further Cox proportional hazards regression models were developed to assess the associations of breathlessness and "persistent and increased phlegm and breathlessness" with mortality rates while controlling for FEV, percent predicted (not shown). The relative hazards ratios were Kristie L Ebi-Kryston As shown in the figure, the distribution of values of FEV1 (percent of predicted) for men who died of chronic bronchitis was much lower than the distribution for men who did not. Using a cut off of less than 65% predicted captures most of the deaths without including too many false positives. The distributions of values were similar for smokers and ex-smokers; 70% of the deaths (34 of 49 smokers and 10 of 14 ex-smokers) occurred in men with a low FEVy.
Discussion
These analyses of a group of male civil servants suggest that low FEV1 is the best single predictor of 15 year mortality from chronic bronchitis; the 6-4% of Adding men with breathlessness slightly increased the number of deaths identified (to 50), the population excess rate (to 1 8 per 1000) and the population excess fraction (to 67%), while increasing the size of the subgroup by 37%, resulting in a lower subgroup specific mortality rate. Adding men with "persistent and increased phlegm and breathlessness" had little effect on prediction. The population excess rates and fractions were smaller for combinations of both low FEVY and either breathlessness or "persistent and increased phlegm and breathlessness" as were the number of deaths identified, making these combinations less useful predictors.
Relative hazards ratios were large (12) for both "persistent and increased phlegm and breathlessness" and breathlessness. The population excess rate and excess fraction was higher for breathlessness than for "persistent and increased phlegm and breathlessness," which suggests that breathlessness may be the better predictor of chronic bronchitis mortality. Relatively few deaths occurred among men with "persistent and increased phlegm and breathlessness" (19 of 64). The remaining measures of respiratory impairment had much smaller relative hazards ratios with chronic bronchitis mortality. Persistent morning phlegm identified approximately the same number ofdeaths as breathlessness, and the population excess rates and fractions were similar. However, the prevalence rate was about three times that of breathlessness, which suggests that breathlessness is a more specific predictor of mortality.
The relatively poor ability ofone MRC definition of chronic bronchitis to predict mortality from chronic bronchitis is interesting. Including in the definition both chronic phlegm production, which was not lethal in this study, and breathlessness, which was, may have weakened its predictive ability. Nearly all ofthe deaths from chronic bronchitis occurred among smokers. Mortality rates from chronic bronchitis have been decreasing,'7 which may in part be due to lower rates of cigarette smoking and to changes in cigarettes, specifically lower average tar yields.'8 Lower tar cigarettes may not have the same influence on chronic phlegm production and airflow obstruction,'9 further diminishing the predictive ability of the definition.
In summary, these analyses suggest that a measure of reduced lung function provides the best prediction in these data of subsequent mortality from chronic bronchitis. If lung function measurements are not available, the next best choice is the question about breathlessness walking on the level. "Persistent and increased phlegm and breathlessness" predicts mortality through its association with airways obstruction.
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